<< Stentys commences enrollment in its comparative stent study | Axsun Technologies reports successful testing of novel OCT imaging integrated light source architecture >>

Read in | English | Español | 한국어 | 简体中文 | 繁體中文 | Bahasa

Results from Phase III pivotal study of FIRMAGON presented

Published on December 4, 2009 at 9:43 AM · No Comments

Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurrence rate in a Phase III pivotal study of FIRMAGON® (monthly degarelix for injection) or monthly leuprolide in prostate cancer patients during the first year of treatment. Prostate cancer patients who received FIRMAGON 240/80 mg/month had a recurrence rate of 7.7% during the first year of treatment compared with 12.9% of patients treated with leuprolide 7.5 mg/month>

Results of the PSA analysis were presented in a poster at the 10th Annual Meeting of the Society of Urologic Oncology, held in conjunction with the World Urological Oncology Federation, on December 3 in Bethesda, MD.

SOURCE Ferring Pharmaceuticals Inc.

ff1c8d67-715a-47c3-b9db-fc9f6cde568a|0|.0

Posted in: Men's Health News | Drug Trial News

Tags: Antigen, Cancer, Congestive Heart Failure, Electrolyte, Endocrinology, Gastroenterology, Gonadotropin, Heart Failure, Hormone, Hypersensitivity, Immunotherapy, Infertility, Methylene Blue, Obstetrics, Oncology, Progesterone, Prostate Cancer, Prostate-Specific Antigen, Testosterone, Urology

Related posts

Sorin Group third quarter revenues decrease 2.1% to €171.4 millionSorin Group: Revenues of €171.4 million, a 2.1% decline (-4.9% as reported) over the same period las...
Light to moderate alcohol intake does not appear to increase risk of all-site cancerA paper from the National Institutes of Health in the United States has evaluated the separate and c...
ASTRO's 53rd Annual Meeting to highlight new cancer advances in MiamiWho: The American Society for Radiation Oncology (ASTRO) - the world's largest radiation oncology so...
Bladder cancer patients missing out on treatment and followups: StudyA new study released this Monday by UCLA's Jonsson Comprehensive Cancer Center shows a large majorit...
Abbott third quarter worldwide sales increase 11.8% to $8.7 billionAbbott today announced financial results for the third quarter ended Sept. 30, 2010.
Combination of cetuximab and cisplatin chemotherapy benefits women with triple-negative breast cancerEuropean researchers have proven for the first time that targeting the epidermal growth factor recep...
FDA extends review on Acetadote for non-acetaminophen acute liver failureCumberland Pharmaceuticals Inc. today announced the U.S. Food and Drug Administration (FDA) has exte...
Parents lack understanding of causes, signs and symptoms of dehydration in childrenDehydration is a condition that can have a significant impact on children and, if left untreated, ma...
Xanodyne Pharmaceuticals, Ferring Pharmaceuticals sign co-promotion agreement for ZipsorXanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development...
Gene therapy may hold promise for cryptorchid individuals risking infertilityEGR4 is a master gene responsible for fertility in cryptorchidism. Is gene therapy going to replace ...
NeoChord commences patient enrollment in its TACT European clinical trialNeoChord, Inc., a venture-backed, Minneapolis-based medical technology company, announced today that...
Boston Scientific to market Bladder Health Network's female urodynamic testing solutions in the U.S.Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a co-marketing ag...
Second-quarter 2009 operating highlights announced by Helicos BiosciencesHelicos BioSciences Corporation (NASDAQ: HLCS) announced today its operating highlights for the quar...
Scientists find key to strengthening immune response to chronic infectionA team of researchers from The Wistar Institute has identified a protein that could serve as a targe...
Vitamin E during pregnancy puts babies at risk of heart defectsNew research by scientists in the Netherlands has found that vitamin E supplements taken during preg...
Biopsy techniques have made PSA test less predictiveProstate specific antigen (PSA) levels typically have correlated with prostate biopsy results in the...
Hormonal components in over-the-counter dietary supplements might promote prostate cancer progressionHormonal components in over-the-counter dietary supplements may promote the progression of prostate ...
Clinical trial to evaluate glioblastoma multiforme vaccine commences at NYUA clinical trial evaluating a brain cancer vaccine in patients with newly diagnosed brain cancer has...
Case studies examine role of hormones, psychology in false pregnancyRecent case studies of pseudocyesis, or false pregnancy, as well as studies of similar conditions in...
HRT shows promise in helping visual memory of postmenopausal womenMany women experience declines in their memory during and after menopause, a change thought to be du...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.